Publication: Pharmacokinetics and safety of PTC596, a novel tubulin-binding agent, in subjects with advanced solid tumors
This research article, published in Clinical Pharmacology in Drug Development, reports the results of a Phase 1 dose-escalation study of PTC596, a novel, orally-administered molecule, being investigated for treatment of solid tumors
Pharmacokinetic data, including bioavailability, absorption, accumulation, and excretion values, for PTC596 given at different doses to human subjects, is provided. Data includes bioavailability and absorption area under the curve
Analysis of adverse effects in patients with a range of solid tumors, along with best overall tumor response to treatment with PTC596 up to 16 weeks, is discussed
Shapiro GI,et al.Clin Pharmacol Drug Dev. 2021;10:940–949.
Once registered, you will be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DIPG-2100031 | March 2023
Sign in or register to access exclusive content on this site